|

Dactinomycin Clinical Trials

5 actively recruiting trials across 3 locations

▲ +1 trial since July 2026

Also known as: (actinomycin-D), Actinomycin A IV, Actinomycin C1, Actinomycin D, Actinomycin I1 +8 more

Pipeline

Phase 2: 1Phase 3: 4

Top Sponsors

  • Children's Oncology Group4
  • St. Jude Children's Research Hospital1

Indications

  • Cancer5
  • Rhabdomyosarcoma2
  • Spindle Cell/Sclerosing Rhabdomyosarcoma1
  • Fusion-Negative Alveolar Rhabdomyosarcoma1
  • Stage IV Mixed Cell Type Kidney Wilms Tumor1

Birmingham, Alabama3 trials

A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)

Children's Hospital of Alabama

Phase 3
Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma

Children's Hospital of Alabama

Phase 3
Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma

Children's Hospital of Alabama

Phase 3

Los Angeles, California1 trial

A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS)

Mattel Children's Hospital UCLA

Phase 3

Palo Alto, California1 trial

Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease

Stanford University

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.